
Join Adam Shlien, PhD, @SickKidsNews, in The Science of Childhood Cancer virtual lecture series Thursday. He will discuss molecular signatures that may improve childhood cancer diagnosis and inform treatment decisions. Sign up now: bit.ly/4hkFOHz

Clinician-scientist Pediatric Oncologist focusing on chemical epigenetics & transcriptional circuitries. Better treatments, less toxicity. @stjuderesearch

Join Adam Shlien, PhD, @SickKidsNews, in The Science of Childhood Cancer virtual lecture series Thursday. He will discuss molecular signatures that may improve childhood cancer diagnosis and inform treatment decisions. Sign up now: bit.ly/4hkFOHz

Amazing new mechanistic insight bridging dna repair to Epigenetics! @ongnghiem and @LabHalic!
St. Jude scientists identified a direct role for PARP1 in chromatin remodeling, revealing for the first time how the protein partially disassembles nucleosomes to make damaged DNA accessible for repair. The findings could lead to more targeted PARP1 inhibitors and potentially reduce treatment toxicity. bit.ly/4zRmFDb

Excited to share that our work is now published in Molecular Cell! We provide the first direct evidence for a role of hexasomes in DNA repair! Wonderful collaboration with @LabHalic, the Shelat labs, and St. Jude Imaging. cell.com/molecular-cell/full…

So excited to work with @JunQiLab on this important study!
New research published in @JExpMed from @DanaFarber’s @JunQiLab and collaborators reveals that AKT inhibitors synergize with EP300 degraders to suppress osteosarcoma growth in vitro and in vivo. These agents positively combine across cancer cells in a manner dependent on control of protein synthesis. ➡️bit.ly/4z13y9G

Researchers identified a potential therapeutic vulnerability in a subset of osteosarcoma. In preclinical models, combining EP300 degradation with AKT inhibition slowed tumor growth and prolonged survival. The findings suggest a potential path toward more personalized treatment. bit.ly/3U3DwDt

We are grateful to the funders of this work for their support: @theNCI @NIH @StJudeResearch @StJude @hopeonwheels @CureSearch @RallyFoundation @ALSFNews @TheVFoundation @curingcancer and the Pediatric Dependencies Accelerator.

This work sets the stage for future work testing more drug-like EP300 degraders with AKT inhibitors in osteosarcoma and indeed, across many, many other types of cancer.

So, in the end, we identified a group of genetically-defined osteosarcomas that are sensitive to EP300 degraders, and identified a fundamental mechanism by which degrader efficacy is affected: the control of protein synthesis. By combining these agents, we get profound synergy.

Using the Cancer Cell Line Encyclopedia, we hypothesized and then showed that cells with elevated transcriptional signatures of protein synthesis are more sensitive to the combination.

But is it restricted to osteosarcoma? To test this, we combined AKT inhibitors and JQAD1 across ~800 cancer cell lines, and demonstrated that…no! This combination works really well across lots of kinds of cancer - so how do you find which ones to combine these compounds in?

This makes it hard for osteosarcoma cells to fight off the effects of JQAD1 by making new EP300. So JQAD1 causes these AKT-dysregulated osteosarcoma cells to slow down…how to make it better? Well, what about combining with AKT inhibitors? We did this and it works!

We found that OSs with mutations that hyperactivate the AKT pathway are sensitive to JQAD1. Activating AKT confers sensitivity to resistant cell lines…but how? We show that AKT activity slows down protein synthesis in osteosarcoma (the opposite of what we usually think!)

This map showed several cancers with selective reliance on EP300, including, sticking out like a sore thumb, osteosarcoma. Osteosarcoma (OS) is an often lethal tumor with limited clinical progress in decades.

But are there other cancers sensitive to JQAD1? How do we find them? Here we used a combined functional genomics and chemical biology approach to identify cancer lineages sensitive to JQAD1 and loss of EP300.

This was the case in the high-risk pediatric tumor neuroblastoma and was the rationale for us to develop JQAD1 - a PROTAC that targets EP300 and spares CBP (doi.org/10.1158/2159-8290.CD…). JQAD1 is well tolerated in animals due to retained CBP, but is very toxic to neuroblastoma.

This was a major effort between the @Adurbinlab @TheAbraLab @JunQiLab and the Ory labs. We pick up on a long-term interest of our labs: the attractive target, EP300. EP300 is a great cancer target because while many tumor cells require it, they often may not need its paralog CBP